News and Views
Nature Cell Biology 8, 785 - 786 (2006)
doi:10.1038/ncb0806-785
Eph tumour suppression: the dark side of Gleevec
Jean Y. J. Wang1
- Jean Y. H. Wang is in the Division of Hematology-Oncology, Department of Medicine, Moores Cancer Center, University of California, San Diego, School of Medicine, La Jolla, CA 92093-0820, USA. e-mail: jywang@ucsd.edu
Abstract
Gleevec inhibits the oncogenic BCR–ABL tyrosine kinase in chronic myelogenous leukaemia and thus safely and effectively suppresses this human cancer. Gleevec also inhibits the normal cellular ABL, a downstream effector of the Eph-receptors, which mediate repulsive cell–cell interactions to regulate axon guidance, angiogenesis and epithelial homeostasis. New work shows that Eph-dependent tumour suppression requires ABL and is blocked by Gleevec, thus cautioning against the indiscriminate use of this drug in cancer therapy.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl?Crk pathwayNature Cell Biology Article (01 Aug 2006)
